93 completed. 93 Phase 2, 11 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 93 | Completed 93 |
| Phase 1 | 11 | Completed 11 |
| Phase 3 | 9 | Completed 9 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis Finerenone, Placebo - Glomerulonephritis | Phase 2 | Completed | Alexandria University | 100 | 2025-04-01 | 2026-05-28 |
| Phase IIa Study for IPG11406 in Patients With Lupus Nephritis IPG11406 - Lupus Nephritis | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 24 | 2025-02-25 | 2026-09-09 |
| A Phase IIa Study in Primary IgA Nephropathy Patients XH-S003 Capsule - IgA Nephropathy | Phase 2 | Completed | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 25 | 2024-12-31 | 2026-09-25 |
| Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN Placebo, HSK39297 50mgBID, HSK39297 100mgBID - IgA Nephropathy (IgAN) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 87 | 2024-10-12 | 2026-05-28 |
| Complement C5 mAb in the Treatment of Anti-GBM Disease Eculizumab - Autoimmune Diseases | Phase 2 | Completed | Peking University First Hospital | 16 | 2024-03-01 | 2025-12-05 |
| A Trial of HRS-5965 Tablets in Primary IgA Nephropathy HRS-5965, Placebo - Primary IgA Nephropathy | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 123 | 2023-12-19 | 2026-07-24 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease Baricitinib, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | Duke University | 8 | 2023-04-20 | 2026-04-24 |
| The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis Curcumin Oral Capsule - Lupus Nephritis, SLE Nephritis | Phase 2 | Completed | Ain Shams University | 72 | 2023-04-01 | 2024-11-20 |
| An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus YTB323 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 21 | 2023-02-28 | 2026-10-15 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) efgartigimod IV, Placebo - Lupus Nephritis | Phase 2 | Completed | argenx | 73 | 2023-02-21 | 2025-12-18 |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| Obinutuzumab in Primary MN Obinutuzumab - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 20 | 2022-02-18 | 2026-10-05 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. HR19042 Capsules, Placebo - IgA Nephropathy | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 316 | 2021-09-09 | 2026-03-12 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy Felzartamab, Placebo - Immunoglobulin A (IgA) Nephropathy | Phase 2 | Completed | HI-Bio, A Biogen Company | 54 | 2021-08-31 | 2026-04-28 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
Showing 20 of 93. Sign in to see all of them.
Lupus Nephritis (27) · Glomerulonephritis, IGA (25) · Glomerulosclerosis, Focal Segmental (17) · Glomerulonephritis, Membranous (14) · Kidney Diseases (13) · Nephrotic Syndrome (13) · Proteinuria (11) · Glomerulonephritis, Membranoproliferative (8) · Lupus Erythematosus, Systemic (8) · Fibrosis (4) · Nephritis (4) · Renal Insufficiency, Chronic (4) · Autoimmune Diseases (3) · Diabetic Nephropathies (3)
Female Urogenital Diseases (93) · Female Urogenital Diseases and Pregnancy Complications (93) · Male Urogenital Diseases (93) · Urogenital Diseases (92) · Urologic Diseases (90) · Nephritis (89) · Kidney Diseases (80) · Immune System Diseases (71) · Autoimmune Diseases (63) · Skin and Connective Tissue Diseases (31) · Connective Tissue Diseases (29) · Lupus Erythematosus, Systemic (20) · Pathological Conditions, Signs and Symptoms (20) · Nephrosis (13)
Prednisone (9) · Mycophenolic Acid (7) · Cyclophosphamide (6) · Rituximab (6) · Methylprednisolone (5) · felzartamab (4) · Sirolimus (3) · Abatacept (2) · Adalimumab (2) · Azathioprine (2) · Cyclosporine (2) · Irbesartan (2) · Prednisolone (2) · avacopan (2) · belimumab (2)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Novartis Pharmaceuticals (7) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Amgen (3) · HI-Bio, A Biogen Company (3) · Mario Negri Institute for Pharmacological Research (3) · Alexion Pharmaceuticals, Inc. (2) · Apellis Pharmaceuticals, Inc. (2) · Aurinia Pharmaceuticals Inc. (2) · Boehringer Ingelheim (2) · Calliditas Therapeutics AB (2) · GlaxoSmithKline (2) · Mayo Clinic (2) · Peking University (2) · Radboud University Medical Center (2)
United States (48) · United Kingdom (22) · Australia (17) · Germany (17) · France (16) · South Korea (15) · Spain (15) · Italy (14) · China (13) · Canada (11) · Belgium (10) · Netherlands (10) · Taiwan (10) · Czechia (9) · Hong Kong (8)
Betty Diamond, MD (2) · Connie L Davis, MD (2) · David Wofsy, MD (2) · Fernando C. Fervenza, M.D., Ph.D. (2) · Jeffrey B Kopp, M.D. (2) · Alex Mercer, PhD (1) · Asher Schachter, M.D. (1) · Betty Diamond, M.D. (1)
PMID 38299639, PMID 35224732, PMID 26032537, PMID 34778952, PMID 40337980, PMID 40465397, PMID 38724717, PMID 15807196, PMID 17660026, PMID 17699247, PMID 19073787, PMID 19932542, PMID 20605876, PMID 21310077, PMID 21356124, PMID 23977072, PMID 25403681, PMID 25457107, PMID 25779381, PMID 26087670, PMID 26198842, PMID 26562836, PMID 27110697, PMID 28363480, PMID 29996800, PMID 30177021, PMID 30361325, PMID 31269364, PMID 32231244, PMID 32755035, PMID 32903623, PMID 33107592, PMID 33685975, PMID 33693991, PMID 33767059, PMID 34124781, PMID 34615636, PMID 35144924, PMID 35230699, PMID 36423588, PMID 36657027, PMID 36915199, PMID 36920755, PMID 37036696, PMID 37192040, PMID 37528520, PMID 37607780, PMID 37772889, PMID 37916620, PMID 37947366
2015 (3), 2017 (3), 2023 (3), 2014 (2), 2005 (1), 2016 (1), 2018 (1), 2019 (1), R01DK049368 (1), R01MD016401 (1), R33DK070341 (1)